ArticleNature cancer2022

Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.

Aya Shiba-Ishii et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.